him hers semaglutide Wegovy maker ends partnership with Hims & Hims & Hers abandons copycat

20262028 could be a big turning point for metabolic medicine

GLP-1 medicines are obviously having a real moment medically and culturally. These once-weekly injectables, which reduce appetite and result in significant, long-lasting (so long as youre taking them) weight loss, have been demonstrated to have a number of important health benefits beyond simply shedding pounds. In March, Novo Nordisks semaglutide (Wegovy) was approved by

CVS's PBM Caremark is apparently negotiating lower Wegovy costs for insurance members

Olubunmi Oladunjoye discusses GLP-1 medications for weight management, including their rise in popularity and possible side effects.

The new Wegovy subscription program with Novo Nordisk is a sign that branded manufacturers want tighter control over: pricing distribution adherence patient experience Translation: the manufacturers (and soon other parties) are building the relationship layer that telehealth platforms assumed was theirs